{
    "Question": "Co-Diagnostics., Inc. (Co-Dx) CES 2024 product highlight and specification",
    "Summary": "Co-Diagnostics, Inc. (Co-Dx)\n\nCES 2024\n\n- Co-Diagnostics, Inc. (Co-Dx) is showcasing its innovative molecular diagnostics platform at CES 2024.\n- The platform offers high accuracy and rapid results for infectious disease testing.\n- It utilizes Co-Dx's proprietary CoPrimer technology, enabling multiplex testing for multiple pathogens in a single reaction.\n- The platform is designed for easy integration into existing laboratory workflows, making it suitable for a wide range of testing environments.\n- Co-Dx's technology has the potential to significantly improve the efficiency and accuracy of infectious disease testing, with applications in healthcare, veterinary medicine, and agriculture.",
    "Summary_cn": "Co-Diagnostics, Inc. (Co-Dx)\n\nCES 2024\n\n- Co-Diagnostics, Inc. (Co-Dx)在CES 2024展示其创新的分子诊断平台。\n- 该平台为传染病检测提供高准确度和快速结果。\n- 它采用了Co-Dx的专有CoPrimer技术，可以在一个反应中进行多种病原体的复合测试。\n- 该平台被设计用于方便地集成到现有的实验室工作流程中，适用于各种检测环境。\n- Co-Dx的技术有潜力显著提高传染病检测的效率和准确性，应用于医疗保健、兽医学和农业等领域。"
}